Intervirology

Intervirology 2000;43:282–287

DNA Vaccination for HIV-1 and SIV

Dan H. Barouch Norman L. Letvin

Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Mass., USA

Key Words

DNA vaccine · Immunization, genetic · HIV-1 · SIV

Abstract

Control of the worldwide AIDS epidemic will only be achieved with a safe and effective prophylactic HIV-1 vaccine. DNA vaccination has recently emerged as a promising vaccine modality that can elicit both humoral and cellular immune responses. HIV-1- and SIV-specific immune responses have been elicited by DNA vaccines in both mice and nonhuman primates. However, these immune responses have not been capable of protecting nonhuman primates against pathogenic AIDS virus challenges. A number of approaches are therefore being investigated to augment DNA vaccine-elicited immune responses.

Introduction

Over 30 million individuals are infected with HIV-1 worldwide. Although the development of highly active antiretroviral therapy represents a major advance for HIV-infected individuals in the western industrialized world, over 90% of HIV-infected individuals worldwide will never benefit from these therapies. It is generally agreed that a safe and effective vaccine will be the only way to control the global AIDS epidemic [1, 2].

Over the past several years there has been a dramatic increase in our understanding of AIDS pathogenesis and the immune responses to HIV-1 infection in humans and SIV infection in rhesus macaques. A wealth of data has established that a vigorous cellular immune response is required for the control of HIV-1 and SIV replication. The early appearance of a robust cytotoxic T lymphocyte (CTL) response was shown to occur coincident with the decline in primary viremia during HIV-1 infection in humans [3–5]. In addition, virus-specific CTL appear to play a critical role in controlling chronic HIV infection [6]. Moreover, a significant inverse correlation was demonstrated between the frequency of HIV-specific CTL and viral load, supporting the significance of the role of CTL in controlling HIV-1 infection [7]. Finally, a vigorous virus-specific helper T cell response has also been shown to correlate with control of viremia [8].

During SIV infection in rhesus macaques, the CTL response appears critical for controlling viral replication. During primary SIV infection, a dramatic rise in circulating and lymph node SIV-specific CTL was found to occur coincident with the control of primary viremia [9–11]. In addition, two groups recently demonstrated that depletion of CD8+ lymphocytes during SIV infection resulted in a dramatic increase in viremia, directly demonstrating the importance of CTL in vivo [12, 13].

KARGER

Fax + 41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com

0300–5526/00/0436–0282$17.50/0

Accessible online at:
www.karger.com/journals/int

Dan H. Barouch
Harvard Medical School and Beth Israel Deaconess Medical Center
330 Brookline Avenue, Boston, MA 02215 (USA)
Tel. +1 617 667 2766, Fax +1 617 667 8210

These data suggest that an effective HIV-1 vaccine must elicit potent cellular immune responses. HIV-1 vaccine development strategies have been recently reviewed [2]. Current strategies include immunization with live attenuated viruses, whole killed viruses, protein subunits, recombinant live vectors, and plasmid DNA. Live attenuated viruses have been shown to generate neutralizing antibody and CTL responses, but the safety of this approach has been questioned. Whole killed viruses and protein subunits are limited by their inability to elicit CTL responses. In contrast, recombinant live vectors and plasmid DNA vaccines can generate cellular immune responses with little or no infectious risks. DNA vaccines offer the additional advantage of being simple and inexpensive to construct, easy to produce in large quantities, and stable for long periods of time. If DNA vaccination proves to be efficacious, production and delivery to individuals in developing nations may be more economically and logistically feasible than with other types of vaccines.

DNA Vaccines for HIV-1 and SIV

DNA vaccination involves the administration of purified plasmid DNA encoding an antigen. Plasmid DNA is typically injected into skeletal muscle or inoculated as plasmid-coated beads by gene gun into the epidermis. The protein is expressed in transfected mammalian cells, including macrophages and dendritic cells, enters into both the MHC class I and class II processing pathways, and elicits strong and persistent humoral and cellular immune responses [14, 15, reviewed in 16–18]. The potential clinical utility of this vaccine modality was demonstrated by Ulmer et al. [19]. In this report, intramuscular injection of a purified plasmid encoding influenza A nucleoprotein elicited potent antigen-specific CTL responses in addition to antibody responses. These immune responses were sufficient to protect mice against challenge with a heterologous strain of influenza A virus.

The potential utility of plasmid DNA as a component of an HIV-1 vaccine has been an area of active investigation. DNA vaccination with plasmids encoding HIV-1 *env* was first shown to elicit Env-specific humoral and cellular immune responses in both mice [20–22] and macaques [23]. A DNA vaccine expressing a soluble form of HIV-1 gp120 also was shown to generate specific antibodies, CD8+ antigen-specific CTL responses, and T_H1-like CD4+ helper T cell-proliferative responses in mice and macaques [24–27]. The immune responses were dose-dependent, boostable and long-lived (>6 months) [25, 28]. SIV-specific CTL responses were also elicited in macaques by DNA vaccination with a plasmid containing SIV *env* and *gag* [29].

Several viral challenge studies have been performed in nonhuman primates to evaluate the protective capacity of the immune responses elicited by DNA vaccines. Complete protection against high-dose challenge with the SF2 strain of HIV-1 was shown following DNA vaccination of chimpanzees with plasmids containing HIV-1 *env* and *gag/pol* [30]. However, the significance of this study remains uncertain, since HIV-1 SF2 replication in chimpanzees occurs at very low levels and is nonpathogenic [31]. In rhesus macaques, six immunizations with DNA encoding SIV *env* genes failed to protect against intravenous challenge with the virulent SIVmac251 isolate [32]. This study did show, however, that viral load was reduced and pathogenicity was attenuated in the vaccinated animals. A second study showed that DNA vaccination of pigtail macaques led to a reduction in viral loads following intrarectal challenge with SIVmne, a viral isolate of intermediate pathogenicity [33]. A study from our group recently demonstrated that SIV *gag* DNA vaccination of rhesus macaques led to the development of secondary CTL responses and reduced viral loads following intravenous challenge with the highly pathogenic SIVmn E660 virus [Egan and Letvin, unpubl. data]. Thus, DNA vaccination with HIV-1 or SIV antigens elicits humoral and cellular immune responses in nonhuman primates. While these results appear promising, DNA vaccine-elicited immune responses have not yet protected primates against a pathogenic viral challenge.

DNA vaccines encoding HIV-1 antigens are also being investigated as potential therapies to augment specific immune responses in HIV-infected patients. Several preliminary studies have shown that DNA vaccines can enhance proliferative T cell or CTL activity [34–36]. However, clinical efficacy of such strategies has not yet been demonstrated.

Strategies to Augment DNA Vaccine-Elicited Immune Responses

The failure of DNA vaccines to generate immune responses capable of protecting nonhuman primates against pathogenic viral challenges has led a number of investigators to develop strategies to augment these immune responses. Two such strategies deserve particular mention: prime-boost approaches and the coadministration of immunomodulator molecules.

Prime-Boost Approaches

One possible approach to augment immune responses elicited by DNA vaccines involves the combination of multiple vaccination modalities. Such multimodal vaccine approaches have largely focused on boosting DNA-primed immune responses with recombinant proteins or recombinant live vectors. DNA priming followed by Env IIIB protein boosting increased antibody responses and successfully protected rhesus macaques against challenge with the nonpathogenic SHIV-IIIB virus [37]. A similar study showed that protein boosting increased DNA-primed antibody responses in cynomolgous macaques, but the immunization regimen described in this study did not result in protection against a nonpathogenic SHIV-Lai challenge [38]. A study in rabbits primed with Env-expressing plasmids showed that Env IIIB protein boosting increased the vaccine-elicited antibody titers and neutralizing activity [39]. Protein boosting thus appears to augment the neutralizing antibody responses to T cell line-adapted, nonpathogenic viruses but has not been able to generate broadly reactive neutralizing antibody responses or provide protection against pathogenic viruses.

A second multimodal vaccine approach is boosting DNA-primed immune responses with recombinant live vectors. DNA priming followed by boosting with recombinant modified vaccinia Ankara (MVA), a pathologically attenuated pox virus, led to high frequency CTL responses and protection of mice against a *Plasmodium berghei* sporozoite challenge [40, 41]. A similar strategy of priming with an SIV Gag epitope DNA vaccine and boosting with recombinant MVA induced potent Gag-specific CTL responses in rhesus macaques [42]. The CTL responses elicited by this approach were more potent that those elicited by DNA alone or recombinant MVA alone. No protection was observed, however, against a pathogenic intrarectal SIVmac251 challenge in at least 2 of the 3 vaccinated animals in this study. Vaccination with DNA plus recombinant vaccinia also did not more effectively control a viral challenge than immunization with DNA alone [43]. Several recent studies in nonhuman primates have evaluated a regimen involving priming with DNA and boosting with recombinant fowlpox viruses. Vaccination of macaques with DNA plus recombinant fowlpox virus led to augmented cellular immune responses and decreased pathogenicity following challenge with a nonpathogenic HIV-1 [44] or a nonpathogenic SHIV-IIIB [45]. In this latter study, the macaques that controlled two SHIV-IIIB challenges also were shown to control a pathogenic SHIV-89.6P challenge. However, it is possible that this protection was mediated in part by the prior SHIV-IIIB exposures.

Recombinant vectors thus appear to have the ability to augment the cellular immune responses primed by DNA vaccines. In certain cases boosting with a recombinant vector has resulted in enhanced protection against nonpathogenic viral challenges. The degree to which boosting with live vectors will augment the ability of nonhuman primates to control pathogenic AIDS virus challenges remains to be determined.

Immunomodulator Molecules

Another strategy for augmenting DNA vaccine-elicited immune responses involves the coadministration of plasmids encoding immunomodulator molecules such as cytokines, chemokines, costimulatory molecules and adhesion molecules. The possibility of rationally designing vaccines or manipulating immune responses has aroused considerable recent interest in this approach.

The utility of plasmid cytokines to modulate DNA vaccine-elicited immune responses was first shown by the demonstration that coinoculation of plasmid GM-CSF enhanced, but plasmid IFN-γ suppressed, the antibody and proliferative T cell responses elicited by a rabies virus-specific DNA vaccine [46]. A large number of studies have since investigated the ability of plasmid cytokines to augment immune responses to DNA vaccines specific for a broad array of antigens including HBV, HCV, HIV-1, influenza, *Plasmodium* and *Leishmania* in small animals. Augmentation of DNA vaccine-elicited HIV-specific cellular immune responses in mice has been reported by the coadministration of plasmid GM-CSF [47, 48], IL-2 [48, 49], IL-12 [47, 48, 50] and IL-15 [51, 52]. Other reports have described the augmentation of DNA vaccine-elicited HIV-1-specific immune responses in mice using plasmids expressing the costimulatory molecule B7-2 [53–55], the adhesion molecules ICAM-1 and LFA-3 [56], and the chemokines RANTES, MIP-1α and MCP-1 [57–59].

A report by our group shows that a plasmid encoding the fusion protein IL-2/Ig, a protein that has IL-2 activity and a longer half-life in vivo, is more effective than plasmid IL-2 in augmenting DNA vaccine-elicited HIV-1 Env-specific antibody and CTL responses in mice [60]. This study also suggests that simultaneous administration of plasmid cytokines with DNA vaccines may not optimally harness this technology, since the highest immune responses were seen when plasmid IL-2/Ig was administered 2 days after the vaccine. We have also demonstrated that plasmid IL-2/Ig administration can substantially aug-

ment antibody and CTL responses elicited by HIV-1 and SIV DNA vaccines in rhesus macaques [Barouch and Letvin, unpubl. results]. Thus, a number of strategies exist for augmenting DNA vaccine-elicited immune responses in both mice as well as nonhuman primates. Whether the degree of augmentation seen to date with these strategies is sufficient to affect clinical parameters following a pathogenic viral challenge is not yet known.

Other Strategies

A number of other strategies for augmenting DNA vaccine-elicited immune responses also are under active investigation. These approaches include changing the vaccine backbone to increase antigen expression by optimizing the usage of mammalian codons in the foreign genes inserted into the DNA vaccines and by increasing the number of CpG sequences in the plasmids to provide the greatest adjuvant effect. Other strategies include attempts to improve the delivery of the vaccine through the use of needle-free injection devices, electroporation to improve the frequency of in vivo transfection, and the development of specific methods to target dendritic cells. Formulations of DNA vaccines with novel chemical and lipid adjuvants are also being assessed.

It has been difficult to generalize from the HIV-1 and SIV vaccine studies in nonhuman primates done to date. Not only have a diversity of immunization regimens been employed, but a variety of markedly different challenge viruses have been used. In the various studies that have been reported, the plasmid DNA constructs employed have differed in their construction and in the methods by which they have been delivered as immunogens. It is clear now that the immunogenicity of plasmid DNA vaccines in higher primates is dependent on the promoters utilized for antigen expression, whether or not the plasmids have been codon-optimized for maximal expression in mammalian cells, the quantity and purity of the DNA used in each inoculation, the route of administration, and the precise formulation of the vaccine. It is also clear that immune protection in nonhuman primates is much more readily achieved against nonpathogenic viruses than against highly virulent pathogenic viruses.

Conclusions

Although the correlates of immunity for vaccine protection against HIV-1 infection have not been definitively established, accumulating evidence over the past several years suggests that candidate AIDS vaccines should generate potent CTL responses as well as neutralizing antibody responses. Plasmid DNA vaccines expressing HIV-1 or SIV antigens are promising in their ability to elicit both cellular and humoral immune responses in mice and nonhuman primates without the infectious risks associated with immunization using attenuated viruses or certain live recombinant vectors. However, immune responses elicited by DNA vaccines alone are unlikely to be of sufficient magnitude to achieve protective immunity against pathogenic AIDS virus challenges. Significant attention, therefore, has focused on developing methods of augmenting DNA vaccine-elicited immune responses, including boosting DNA-primed responses with recombinant proteins or recombinant live vectors and coimmunizing with immunomodulatory molecules. Preliminary data suggest that these strategies can result in significantly augmented HIV-1- and SIV-specific immune responses. However, none of these approaches has yet been shown to protect nonhuman primates against a pathogenic AIDS virus challenge.

Acknowledgments

The authors thank Dr. John Shiver for critically reviewing the manuscript.

References

1 Cohen OJ, Fauci AS: HIV/AIDS in 1998 – Gaining the upper hand? JAMA 1998;280:87–88.

2 Letvin NL: Progress in the development of an HIV-1 vaccine. Science 1998;280:1875–1880.

3 Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68:4650–4655.

4 Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MBA: Virus-specific CD8+ cytolytic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103–6110.

5 Pantaleo G, Demarest JF, Soudeyns H, Graziosi C, Denis F, Adelsberger JW, Borrow P, Saag MS, Shaw GM, Sekaly RP, Fauci AS: Major expansion of CD8+ T cells with a predominant Vβ usage during the primary immune response to HIV. Nature 1994;370:463–467.

6 Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ: Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. New Engl J Med 1997;337:1267–1274.

7 Ogg GS, Jin X, Bonhoeffer S, Dunbar PR, Nowak MA, Monard S, Segal JP, Cao Y, Rowland-Jones SL, Cerundolo V, Hurley A, Markowitz M, Ho DD, Nixon DF, McMichael AJ: Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998;279:2103–2106.

8 Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, Walker BD: Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997;278:1447–1450.

9 Yasutomi Y, Reimann KA, Lord CI, Miller MD, Letvin NL: Simian immunodeficiency virus specific CD8+ lymphocyte response in acutely infected rhesus monkeys. J Virol 1993;67:1707–1711.

10 Reimann KA, Tenner-Racz K, Racz P, Montefiori DC, Yasutomi Y, Lin W, Ransil BJ, Letvin NL: Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. J Virol 1994;68:2362–2370.

11 Chen ZW, Kou ZC, Lekutis C, Shen L, Zhou D, Halloran M, Li J, Sodroski J, Lee-Parritz D, Letvin NL: T cell receptor Vβ repertoire in an acute infection of rhesus monkeys with simian immunodeficiency viruses and a chimeric simian-human immunodeficiency virus. J Exp Med 1995;182:21–31.

12 Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, Racz P, Tenner-Racz K, Dalesandro M, Scallon BJ, Ghrayeb J, Forman MA, Montefiori DC, Rieber EP, Letvin NL, Reimann KA: Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999;283:857–860.

13 Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, Irwin CE, Safrit JT, Mittler J, Weinberger L, Kostrikis LG, Zhang L, Perelson AS, Ho DD: Dramatic rise in plasma viremia after CD8+ T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 1999;189:991–998.

14 Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL: Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465–1468.

15 Tang DC, Devit M, Johnson SA: Genetic immunization is a simple method for eliciting an immune response. Nature 1992;356:152–154.

16 McDonnell WM, Askari FK: DNA vaccines. New Engl J Med 1996;334:42–45.

17 Donnelly JJ, Ulmer JB, Shiver JW, Liu MA: DNA vaccines. Annu Rev Immunol 1997;15:617–648.

18 Chattergoon M, Boyer J, Weiner DB: Genetic immunization: A new era in vaccines and immune therapies. FASEB J 1997;11:753–763.

19 Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A, Hawe LA, Leander KR, Martinez D, Perry HC, Shiver JW, Montgomery DL, Liu MA: Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259:1745–1749.

20 Wang B, Boyer J, Srikantan V, Coney L, Carrano R, Phan C, Merva M, Dang K, Agadjanyan M, Gilbert L, Ugen KE, Williams WV, Weiner DB: DNA inoculation induces neutralizing immune responses against human immunodeficiency virus type-1 in mice and nonhuman primates. DNA Cell Biol 1993;12:799–805.

21 Wang B, Ugen EK, Srikantan V, Agadjanyan M, Dang K, Refaeli Y, Sato AI, Boyer JD, Williams WV, Weiner DB: Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993;90:4156–4160.

22 Lu S, Santoro JC, Fuller DH, Haynes JR, Robinson HL: Use of DNAs expressing HIV-1 env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology 1995;209:147–154.

23 Wang B, Boyer J, Srikantan V, Ugen K, Gilbert L, Phan C, Dang K, Merva M, Agadjanyan M, Newman M, Carrano R, McCallus D, Coney L, Williams WV, Weiner DB: Induction of humoral and cellular immune responses to the human immunodeficiency virus type 1 in nonhuman primates. Virology 1995;221:102–112.

24 Shiver JW, Perry HC, Davies ME, Freed DC, Liu MA: Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination. Ann NY Acad Sci 1995;772:198–208.

25 Shiver JW, Davies ME, Perry HC, Freed DC, Liu MA: Humoral and cellular immunities elicited by HIV-1 DNA vaccination. J Pharm Sci 1996;85:1317–1324.

26 Liu MA, Yasutomi Y, Davies ME, Perry HC, Letvin NL, Shiver JW: Vaccination of mice and nonhuman primates using HIV gene-containing DNA. Antibiot Chemother 1996;48:100–104.

27 Lekutis C, Shiver JW, Liu MA, Letvin NL: HIV-1 env DNA vaccine administered to rhesus monkeys elicits MHC class II-restricted CD4+ T helper cells that secrete IFN-γ and TNF-α. J Immunol 1997;158:4471–4477.

28 Shiver JW, Davies ME, Yasutomi Y, Perry HC, Freed DC, Letvin NL, Liu MA: Anti-HIV env immunities elicited by nucleic acid vaccines. Vaccine 1997;15:884–887.

29 Yasutomi Y, Robinson HL, Lu S, Mustafa F, Lekutis C, Arthos J, Mullins JI, Voss G, Manson K, Wyand M, Letvin NL: Simian immunodeficiency virus-specific cytotoxic T-lymphocyte induction through DNA vaccination of rhesus macaques. J Virol 1996;70:678–681.

30 Boyer JD, Ugen KE, Wang B, Agadjanyan M, Gilbert L, Bagarazzi ML, Chattergoon M, Frost P, Javadian A, Williams WV, Refaeli Y, Ciccarelli RB, McCallus D, Coney L, Weiner DB: Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat Med 1997;3:526–532.

31 Kennedy RC: DNA vaccination for HIV. Nat Med 1997;3:501–502.

32 Lu S, Arthos J, Montefiori DC, Yasutomi Y, Manson K, Mustafa F, Johnson E, Santoro JC, Wissink J, Mullins JI, Haynes JR, Letvin NL, Wyand M, Robinson HL: Simian immunodeficiency virus DNA vaccine trial in macaques. J Virol 1996;70:3978–3991.

33 Haigwood NL, Pierce CC, Robertson MN, Watson AJ, Montefiori DC, Rabin M, Lynch JB, Kuller L, Thompson J, Morton WR, Benveniste RE, Hu SL, Greenberg P, Mossman SP: Protection from pathogenic SIV challenge using multigenic DNA vaccines. Immunol Lett 1999;66:183–188.

34 Calarota S, Bratt G, Nordlund S, Hinkula J, Leandersson AC, Sandstrom E, Wahren B: Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998;351:1320–1325.

35 MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Gluckman SJ, Bagarazzi ML, Chattergoon MA, Baine Y, Higgins TJ, Ciccarelli RB, Coney LR, Ginsberg RS, Weiner DB: First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response. J Infect Dis 1998;178:92–100.

36 Boyer JD, Chattergoon MA, Ugen KE, Shah A, Bennett M, Cohen A, Nyland S, Lacy KE, Bagarazzi ML, Higgins TJ, Baine Y, Ciccarelli RB, Ginsberg RS, MacGregor RR, Weiner DB: Enhancement of cellular immune response in HIV-1 seropositive individuals: A DNA-based trial. Clin Immunol 1999;90:100–107.

37 Letvin NL, Montefiori DC, Yasutomi Y, Perry HC, Davies ME, Lekutis C, Alroy M, Freed DC, Lord CI, Handt LK, Liu MA, Shiver JW: Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci USA 1997;94:9378–9383.
38 Putkonen P, Quesada-Rolander M, Leanderson AC, Schwartz S, Thorstensson R, Okuda K, Wahren B, Hinkula J: Immune responses but no protection against SHIV by gene-gun delivery of HIV-1 DNA followed by recombinant subunit protein boosts. Virology 1998;250:293–301.
39 Richmond JF, Lu S, Santoro JC, Weng J, Hu SL, Montefiori DC, Robinson HL: Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. J Virol 1998;72:9092–9100.
40 Hanke T, Blanchard TJ, Schneider J, Hannan CM, Becker M, Gilbert SC, Hill AVS, Smith GL, McMichael AJ: Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regimen. Vaccine 1998;16:439–445.
41 Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, Hannan CM, Becker M, Sinden R, Smith GL, Hill AVS: Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 1998;4:397–402.
42 Hanke T, Samuel RV, Blanchard TJ, Neumann VC, Allen TM, Boyson JE, Sharpe SA, Cook N, Smith GL, Watkins DI, Cranage MP, McMichael AJ: Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol 1999;73:7524–7532.
43 Fuller DH, Simpson L, Cole KS, Clements JE, Panicali DL, Montelaro RC, Murphey-Corb M, Haynes JR: Gene gun-based nucleic acid immunization alone or in combination with recombinant vaccinia vectors suppresses virus burden in rhesus macaques challenged with a heterologous SIV. Immunol Cell Biol 1997;75:389–396.
44 Kent SJ, Zhao A, Best SJ, Chandler JD, Boyle DB, Ramshaw IA: Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J Virol 1998;72:10180–10188.
45 Robinson HL, Montefiori DC, Johnson RP, Manson KH, Kalish ML, Lifson JD, Rizvi TA, Lu S, Hu SL, Mazzara GP, Panicali DL, Herndon JG, Glickman R, Candido MA, Lydy SL, Wyand MS, McClure HM: Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 1999;5:526–534.
46 Xiang Z, Ertl HCJ: Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 1995;2:129–135.
47 Okada E, Sasaki S, Ishii N, Aoki I, Yasuda T, Nishioka K, Fukushima J, Miyazaki JI, Wahren B, Okuda K: Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J Immunol 1997;159:3638–3647.
48 Kim JJ, Simbiri KA, Sin JI, Dang K, Oh J, Dentchev T, Lee D, Nottingham LK, Chalian AA, McCallus D, Ciccarelli R, Agadjanyan MG, Weiner DB: Cytokine molecular adjuvants modulate immune responses induced by DNA vaccine constructs for HIV-1 and SIV. J Interferon Cytokine Res 1999;19:77–84.
49 Xin KQ, Hamajima K, Sasaki S, Honsho A, Tsuji T, Ishii N, Cao XR, Lu Y, Fukushima J, Shapshak P, Kawamoto S, Okuda K: Intranasal administration of human immunodeficiency virus type-1 (HIV-1) DNA vaccine with interleukin-2 expression plasmid enhances cell-mediated immunity against HIV-1. Immunology 1998;94:438–444.
50 Kim JJ, Ayyavoo V, Bagarazzi ML, Chattergoon MA, Dang K, Wang B, Boyer JD, Weiner DB: In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol 1997;158:816–826.
51 Kim JJ, Trivedi NN, Nottingham LK, Morrison L, Tsai A, Hu Y, Mahalingam S, Dang K, Ahn L, Doyle NK, Wilson DM, Chattergoon MA, Chalian AA, Boyer JD, Agadjanyan MG, Weiner DB: Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur J Immunol 1998;28:1089–1103.
52 Xin KQ, Hamajima K, Sasaki S, Tsuji T, Watabe S, Okuda E, Okuda K: IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. Vaccine 1999;17:858–866.
53 Kim JJ, Bagarazzi ML, Trivedi N, Hu Y, Kazahaya K, Wilson DM, Ciccarelli R, Chattergoon MA, Dang K, Mahalingam S, Chalian AA, Agadjanyan MG, Boyer JD, Wang B, Weiner DB: Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nat Biotechnol 1997;15:641–646.
54 Kim JJ, Ayyavoo V, Bagarazzi ML, Chattergoon M, Boyer JD, Wang B, Weiner DB: Development of a multicomponent candidate vaccine for HIV-1. Vaccine 1997;15:879–883.
55 Kim JJ, Nottingham LK, Wilson DM, Bagarazzi ML, Tsai A, Morrison LD, Javadian A, Chalian AA, Agadjanyan MG, Weiner DB: Engineering DNA vaccines via co-delivery of costimulatory molecule genes. Vaccine 1998;16:1828–1835.
56 Kim JJ, Tsai A, Nottingham LK, Morrison L, Cunning DM, Oh J, Lee DJ, Dang K, Dentchev T, Chalian AA, Agadjanyan MG, Weiner DB: Intracellular adhesion molecule-1 modulates beta-chemokines and directly costimulates T cells in vivo. J Clin Invest 1999;103:869–877.
57 Kim JJ, Nottingham LK, Sin JI, Tsai A, Morrison L, Oh J, Dang K, Hu Y, Kazahaya K, Bennett M, Dentchev T, Wilson DM, Chalian AA, Boyer JD, Agadjanyan MG, Weiner DB: CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. Vaccine 1998;16:1828–1835.
58 Xin KQ, Lu Y, Hamajima K, Fukushima J, Yang J, Inamura K, Okuda K: Immunization of RANTES expression plasmid with a DNA vaccine enhances HIV-1-specific immunity. Clin Immunol 1999;92:90–96.
59 Lu Y, Xin KQ, Hamajima K, Tsuji T, Aoki I, Yang J, Sasaki S, Fukushima J, Yoshimura T, Toda S, Okada E, Okuda K: Macrophage inflammatory protein-1α (MIP-1α) expression plasmid enhances DNA vaccine-induced immune response against HIV-1. Clin Exp Immunol 1999;115:335–341.
60 Barouch DH, Santra S, Steenbeke TD, Zheng XX, Perry HC, Davies ME, Freed DC, Craiu A, Strom TB, Shiver JW, Letvin NL: Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J Immunol 1998;161:1875–1882.